$HCSG
HEALTHCARE SERVICES GROUP INC Stock $hcsg

$hcsg Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000073101223000065 Filed on April 28, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$418.9M	$417.2M	$426.8M
YoY Change	-1.39%	-2.24%	4.67%
Cost Of Revenue	$367.7M	$361.0M	$373.3M
YoY Change	-3.07%	-3.29%	10.89%
Gross Profit	$51.20M	$56.25M	$53.55M
YoY Change	12.57%	5.05%	-24.72%
Gross Profit Margin	12.22%	13.48%	12.55%
Selling, General & Admin	$41.43M	$40.05M	$35.74M
YoY Change	41.49%	12.06%	-10.63%
% of Gross Profit	80.91%	71.19%	66.74%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$3.595M	$3.720M	$4.147M
YoY Change	49.79%	-10.3%	14.97%
% of Gross Profit	7.02%	6.61%	7.74%
Operating Expenses	$41.43M	$40.05M	$35.74M
YoY Change	41.49%	12.06%	-10.63%
Operating Profit	$9.774M	$16.21M	$17.81M
YoY Change	-39.69%	-9.03%	-42.81%
Interest Expense	$1.636M	-$1.751M	-$509.0K
YoY Change	-467.57%	244.01%	42.18%
% of Operating Profit	16.73%	-10.81%	-2.86%
Other Income/Expense, Net
YoY Change
Pretax Income	$11.41M	$17.56M	$15.78M
YoY Change	38.3%	11.25%	-52.11%
Income Tax	$2.812M	$4.872M	$4.452M
% Of Pretax Income	24.65%	27.75%	28.21%
Net Earnings	$8.598M	$12.68M	$11.33M
YoY Change	26.07%	11.96%	-54.05%
Net Earnings / Revenue	2.05%	3.04%	2.65%
Basic Earnings Per Share	$0.12	$0.17	$0.15
Diluted Earnings Per Share	$0.12	$0.17	$0.15
COMMON SHARES
Basic Shares Outstanding	74.20M shares	74.39M shares	74.33M shares
Diluted Shares Outstanding	74.57M shares	74.52M shares	74.33M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$121.8M	$112.1M	$140.1M
YoY Change	-5.67%	-19.94%	-43.84%
Cash & Equivalents	$28.66M	$16.15M	$32.90M
Short-Term Investments	$93.19M	$95.99M	$107.2M
Other Short-Term Assets	$26.28M	$25.19M	$35.79M
YoY Change	-22.35%	-29.63%	-12.27%
Inventory	$19.98M	$20.23M	$24.82M
Prepaid Expenses	$26.28M	$25.19M	$35.79M
Receivables	$380.1M	$350.8M	$319.1M
Other Receivables	$926.0K	$1.748M	$5.049M
Total Short-Term Assets	$549.1M	$510.1M	$524.8M
YoY Change	5.22%	-2.81%	-8.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$26.93M	$23.40M	$26.70M
YoY Change	5.07%	-12.37%	-3.6%
Goodwill	$75.53M	$75.53M	$75.53M
YoY Change	0.0%	0.0%	47.85%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$65.93M	$760.0K	$71.95M
YoY Change	0.24%	-98.94%	-13.21%
Total Long-Term Assets	$212.7M	$209.0M	$221.7M
YoY Change	-2.54%	-5.7%	5.26%
TOTAL ASSETS
Total Short-Term Assets	$549.1M	$510.1M	$524.8M
Total Long-Term Assets	$212.7M	$209.0M	$221.7M
Total Assets	$761.8M	$719.1M	$746.5M
YoY Change	2.93%	-3.67%	-4.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$65.62M	$64.35M	$64.04M
YoY Change	-1.27%	0.49%	34.1%
Accrued Expenses	$81.24M	$61.46M	$93.97M
YoY Change	-20.95%	-34.6%	3.04%
Deferred Revenue
YoY Change
Short-Term Debt	$40.00M	$35.00M	$10.00M
YoY Change	300.0%	250.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$189.7M	$162.2M	$174.3M
YoY Change	3.12%	-6.96%	18.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$121.5M	$6.448M	$8.696M
YoY Change	1796.74%	-25.85%	-93.91%
Total Long-Term Liabilities	$121.5M	$6.448M	$8.696M
YoY Change	1796.74%	-25.85%	-93.91%
TOTAL LIABILITIES
Total Short-Term Liabilities	$189.7M	$162.2M	$174.3M
Total Long-Term Liabilities	$121.5M	$6.448M	$8.696M
Total Liabilities	$311.2M	$168.6M	$183.0M
YoY Change	63.48%	-7.86%	-36.83%
SHAREHOLDERS EQUITY
Retained Earnings	$175.8M	$167.2M	$179.4M
YoY Change	3.25%	-6.82%	-14.57%
Common Stock	$306.6M	$304.3M	$297.1M
YoY Change	2.49%	2.45%	3.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$28.59M
YoY Change			236.63%
Treasury Stock Shares			2.122M shares
Shareholders Equity	$450.6M	$440.6M	$446.6M
YoY Change
Total Liabilities & Shareholders Equity	$761.8M	$719.1M	$746.5M
YoY Change	2.93%	-3.67%	-4.64%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	$8.598M	$12.68M	$11.33M
YoY Change	26.07%	11.96%	-54.05%
Depreciation, Depletion And Amortization	$3.595M	$3.720M	$4.147M
YoY Change	49.79%	-10.3%	14.97%
Cash From Operating Activities	$7.403M	-$16.29M	-$30.18M
YoY Change	-17.91%	-46.03%	-961.85%
INVESTING ACTIVITIES
Capital Expenditures	$1.087M	$1.010M	$1.407M
YoY Change	-192.67%	-28.22%	65.53%
Acquisitions
YoY Change
Other Investing Activities	$1.193M	$267.0K	$32.00K
YoY Change	-82.21%	734.38%	-101.1%
Cash From Investing Activities	$106.0K	-$743.0K	-$1.375M
YoY Change	-98.08%	-45.96%	-62.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$25.00K
YoY Change			8.7%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.000M	$6.907M	-$6.338M
YoY Change	-131.71%	-208.98%	-59.04%
NET CHANGE
Cash From Operating Activities	7.403M	-$16.29M	-$30.18M
Cash From Investing Activities	106.0K	-$743.0K	-$1.375M
Cash From Financing Activities	5.000M	$6.907M	-$6.338M
Net Change In Cash	12.51M	-$10.13M	-$37.90M
YoY Change	-1127.01%	-73.28%	141.74%
FREE CASH FLOW
Cash From Operating Activities	$7.403M	-$16.29M	-$30.18M
Capital Expenditures	$1.087M	$1.010M	$1.407M
Free Cash Flow	$6.316M	-$17.30M	-$31.59M
YoY Change	-38.02%	-45.23%	-1291.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000731012
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://hcsgcorp.com/20230331#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://hcsgcorp.com/20230331#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	0-12015
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	HEALTHCARE SERVICES GROUP, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	PA
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	23-2018365
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3220 Tillman Drive
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Bensalem
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19020
CY2023Q1	dei	City Area Code CityAreaCode	215
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	639-4274
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	HCSG
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74195000	shares
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16153000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26279000	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	95985000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	95200000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	73030000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	70192000	usd
CY2023Q1	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	350784000	usd
CY2022Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	336777000	usd
CY2023Q1	us-gaap	Other Inventory OtherInventory	20229000	usd
CY2022Q4	us-gaap	Other Inventory OtherInventory	21164000	usd
CY2023Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	1748000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	6629000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	25188000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	22583000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	510087000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	508632000	usd
CY2022Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	23166000	usd
CY2023Q1	hcsg	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	23400000	usd
CY2022Q4	hcsg	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	22975000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	75529000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	75529000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	33941000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	32738000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14743000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15946000	usd
CY2023Q1	us-gaap	Allowance For Notes And Loans Receivable Noncurrent AllowanceForNotesAndLoansReceivableNoncurrent	3837000	usd
CY2022Q4	us-gaap	Allowance For Notes And Loans Receivable Noncurrent AllowanceForNotesAndLoansReceivableNoncurrent	3273000	usd
CY2023Q1	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	32327000	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	32609000	usd
CY2023Q1	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	34312000	usd
CY2022Q4	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	33493000	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	27975000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	28338000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	760000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	812000	usd
CY2023Q1	us-gaap	Assets Assets	719133000	usd
CY2022Q4	us-gaap	Assets Assets	718334000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	64351000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	68296000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20394000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	42704000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	17088000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	17835000	usd
CY2023Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	35000000	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	25000000	usd
CY2023Q1	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	1357000	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	1618000	usd
CY2023Q1	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	23974000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	162164000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	178619000	usd
CY2023Q1	us-gaap	Workers Compensation Liability Noncurrent WorkersCompensationLiabilityNoncurrent	67100000	usd
CY2022Q4	us-gaap	Workers Compensation Liability Noncurrent WorkersCompensationLiabilityNoncurrent	65541000	usd
CY2023Q1	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	34263000	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	33764000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8586000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8097000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6448000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6141000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	76329000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	76161000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74194000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74088000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	763000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	762000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	303582000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	302304000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	167190000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	154495000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2270000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3477000	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2135000	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2073000	shares
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	28693000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	27912000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	440572000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	426172000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	719133000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	718334000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	417230000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	426811000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	360978000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	373262000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40047000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	35736000	usd
CY2023Q1	hcsg	Investment Income And Other InvestmentIncomeAndOther	3102000	usd
CY2022Q1	hcsg	Investment Income And Other InvestmentIncomeAndOther	-1523000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1751000	usd
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-509000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	17556000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	15781000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4872000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4452000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	12684000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	11329000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.17
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.15
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.17
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.15
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74497000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74326000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74518000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74333000	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	12684000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	11329000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1207000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5269000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	13891000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6060000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	12684000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	11329000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3720000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4147000	usd
CY2023Q1	hcsg	Accounts And Financing Receivable Credit Loss Expense Reversal AccountsAndFinancingReceivableCreditLossExpenseReversal	6907000	usd
CY2022Q1	hcsg	Accounts And Financing Receivable Credit Loss Expense Reversal AccountsAndFinancingReceivableCreditLossExpenseReversal	2851000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	43000	usd
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2058000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2396000	usd
CY2023Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	533000	usd
CY2022Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	561000	usd
CY2023Q1	hcsg	Unrealized Gain Loss On Securities Related To Deferred Compensation Fund UnrealizedGainLossOnSecuritiesRelatedToDeferredCompensationFund	1502000	usd
CY2022Q1	hcsg	Unrealized Gain Loss On Securities Related To Deferred Compensation Fund UnrealizedGainLossOnSecuritiesRelatedToDeferredCompensationFund	-4074000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	336000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1760000	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-128000	usd
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-173000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	20633000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	27222000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-935000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1195000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4076000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2462000	usd
CY2023Q1	hcsg	Increase Decrease In Deferred Compensation Funding IncreaseDecreaseInDeferredCompensationFunding	-683000	usd
CY2022Q1	hcsg	Increase Decrease In Deferred Compensation Funding IncreaseDecreaseInDeferredCompensationFunding	-3605000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-6422000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-3051000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	-21167000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	-24933000	usd
CY2023Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	1748000	usd
CY2022Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-3764000	usd
CY2023Q1	us-gaap	Increase Decrease In Workers Compensation Liabilities IncreaseDecreaseInWorkersCompensationLiabilities	2366000	usd
CY2022Q1	us-gaap	Increase Decrease In Workers Compensation Liabilities IncreaseDecreaseInWorkersCompensationLiabilities	3056000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	713000	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-7905000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16290000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30182000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	57000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	152000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1010000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1407000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1525000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	210000	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	2223000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	475000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1135000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1519000	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	usd
CY2022Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	114000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-743000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1375000	usd
CY2023Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	0	usd
CY2022Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	15704000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	410000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2223000	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	10000000	usd
CY2022Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	10000000	usd
CY2023Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	870000	usd
CY2022Q1	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	1069000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6907000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6338000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10126000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-37895000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26279000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70794000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16153000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32899000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	426172000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	12684000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1207000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	13891000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	870000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1973000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	19000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	440572000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	452677000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	11329000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5269000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6060000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	410000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1069000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2298000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	524000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1512000	usd
CY2022Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.21
CY2022Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	15859000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	25000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	59000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	446637000	usd
CY2023Q1	hcsg	Revenue From Contract With Customer Renewal Term RevenueFromContractWithCustomerRenewalTerm	P1Y
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	In preparing financial statements in conformity with U.S. GAAP, estimates and assumptions are made that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities, and the reported amounts of revenues and expenses. Actual results could differ from those estimates. Significant estimates are used in determining, but are not limited to, the Company’s allowance for doubtful accounts, accrued insurance claims, deferred taxes and reviews for potential impairment. The estimates are based upon various factors including current and historical trends, as well as other pertinent industry and regulatory authority information. Management regularly evaluates this information to determine if it is necessary to update the basis for its estimates and to adjust for known changes.
CY2023Q1	us-gaap	Contract With Customer Timing Of Satisfaction Of Performance Obligation And Payment ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment	The Company’s payment terms with customers on promissory notes can vary based on several factors and the circumstances of each promissory note, however most promissory notes mature over a 1 to 4 year period. Similar to accounts receivable, each reporting period the Company evaluates the collectability of outstanding notes receivable balances and records an allowance for doubtful accounts representing an estimate of future expected credit losses
CY2023Q1	hcsg	Period Of Amortization Of Inventories And Supplies PeriodOfAmortizationOfInventoriesAndSupplies	P24M
CY2022Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2023Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments that are subject to credit risk are cash and cash equivalents, marketable securities, deferred compensation funding and accounts and notes receivable. At March 31, 2023 and December 31, 2022, the majority of the Company’s cash and cash equivalents and marketable securities were held in one large financial institution located in the United States. The Company’s marketable securities are fixed income investments which are highly liquid and can be readily purchased or sold through established markets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s customers are concentrated in the healthcare industry and are primarily providers of long-term care. The revenues of many of the Company’s customers are highly reliant on Medicare, Medicaid and third party payors’ reimbursement funding rates. New legislation or changes in existing regulations could directly impact the governmental reimbursement programs in which the Company’s customers participate. As a result, the Company may not realize the full effects such programs may have on the Company’s customers until these laws are fully implemented and governmental agencies issue applicable regulations or guidance.</span></div>
CY2022Q4	hcsg	Concentration Risk Numberof Financial Institutions Holding Cashand Cash Equivalentsand Marketable Securities ConcentrationRiskNumberofFinancialInstitutionsHoldingCashandCashEquivalentsandMarketableSecurities	1	institution
CY2023Q1	hcsg	Concentration Risk Numberof Financial Institutions Holding Cashand Cash Equivalentsand Marketable Securities ConcentrationRiskNumberofFinancialInstitutionsHoldingCashandCashEquivalentsandMarketableSecurities	1	institution
CY2023Q1	hcsg	Revenue From Contract With Customer Renewal Term RevenueFromContractWithCustomerRenewalTerm	P1Y
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1400000	usd
CY2023Q1	us-gaap	Revenue Performance Obligation Description Of Timing RevenuePerformanceObligationDescriptionOfTiming	The Company’s contracts with customers typically provide for an initial term of one year, with renewable one year service terms, cancellable by either party upon 30 to 90 days’ notice after an initial period of 60 to 120 days.
CY2023Q1	hcsg	Revenue From Contract With Customer Renewal Term RevenueFromContractWithCustomerRenewalTerm	P1Y
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	99000000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2023Q1	hcsg	Accounts Notes Loansand Financing Receivable Gross Current AccountsNotesLoansandFinancingReceivableGrossCurrent	423814000	usd
CY2022Q4	hcsg	Accounts Notes Loansand Financing Receivable Gross Current AccountsNotesLoansandFinancingReceivableGrossCurrent	406969000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	73030000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	70192000	usd
CY2023Q1	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	350784000	usd
CY2022Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	336777000	usd
CY2023Q1	us-gaap	Notes And Loans Receivable Gross Noncurrent NotesAndLoansReceivableGrossNoncurrent	36164000	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Gross Noncurrent NotesAndLoansReceivableGrossNoncurrent	35882000	usd
CY2023Q1	us-gaap	Allowance For Notes And Loans Receivable Noncurrent AllowanceForNotesAndLoansReceivableNoncurrent	3837000	usd
CY2022Q4	us-gaap	Allowance For Notes And Loans Receivable Noncurrent AllowanceForNotesAndLoansReceivableNoncurrent	3273000	usd
CY2023Q1	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	32327000	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	32609000	usd
CY2023Q1	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	383111000	usd
CY2022Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	369386000	usd
CY2023Q1	us-gaap	Financing Receivable Nonaccrual Interest Income FinancingReceivableNonaccrualInterestIncome	600000	usd
CY2022Q1	us-gaap	Financing Receivable Nonaccrual Interest Income FinancingReceivableNonaccrualInterestIncome	300000	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff Year One Originated Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffYearOneOriginatedCurrentFiscalYear	0	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff Year Two Originated Fiscal Year Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear	0	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff Year Three Originated Two Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear	0	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff Year Four Originated Three Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffYearFourOriginatedThreeYearsBeforeCurrentFiscalYear	0	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff Year Five Originated Four Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffYearFiveOriginatedFourYearsBeforeCurrentFiscalYear	0	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff Originated More Than Five Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear	51000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	51000	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Recovery Year One Originated Current Fiscal Year FinancingReceivableAllowanceForCreditLossRecoveryYearOneOriginatedCurrentFiscalYear	0	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Recovery Year Two Originated Fiscal Year Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossRecoveryYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear	0	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Recovery Year Three Originated Two Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossRecoveryYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear	0	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Recovery Year Four Originated Three Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossRecoveryYearFourOriginatedThreeYearsBeforeCurrentFiscalYear	0	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Recovery Year Five Originated Four Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossRecoveryYearFiveOriginatedFourYearsBeforeCurrentFiscalYear	0	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Recovery Originated More Than Five Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossRecoveryOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear	0	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	0	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff After Recovery Year One Originated Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffAfterRecoveryYearOneOriginatedCurrentFiscalYear	0	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff After Recovery Year Two Originated Fiscal Year Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffAfterRecoveryYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear	0	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff After Recovery Year Three Originated Two Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffAfterRecoveryYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear	0	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff After Recovery Year Four Originated Three Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffAfterRecoveryYearFourOriginatedThreeYearsBeforeCurrentFiscalYear	0	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff After Recovery Year Five Originated Four Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffAfterRecoveryYearFiveOriginatedFourYearsBeforeCurrentFiscalYear	0	usd
CY2023Q1	hcsg	Financing Receivable Allowance For Credit Loss Writeoff After Recovery Originated More Than Five Years Before Current Fiscal Year FinancingReceivableAllowanceForCreditLossWriteoffAfterRecoveryOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear	51000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Loss Writeoff After Recovery FinancingReceivableAllowanceForCreditLossWriteoffAfterRecovery	51000	usd
CY2023Q1	us-gaap	Accounts And Financing Receivable Allowance For Credit Loss AccountsAndFinancingReceivableAllowanceForCreditLoss	76867000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	100000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	50794000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	66601000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	3453000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5259000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	68407000	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	6863000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Loss Writeoff After Recovery FinancingReceivableAllowanceForCreditLossWriteoffAfterRecovery	51000	usd
CY2023Q1	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	1648000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8460000	usd
CY2022Q4	us-gaap	Accounts And Financing Receivable Allowance For Credit Loss AccountsAndFinancingReceivableAllowanceForCreditLoss	73464000	usd
CY2023Q1	hcsg	Accounts And Financing Receivable Allowance For Credit Loss Writeoff AccountsAndFinancingReceivableAllowanceForCreditLossWriteoff	3504000	usd
CY2023Q1	hcsg	Accounts And Financing Receivable Credit Loss Expense Reversal AccountsAndFinancingReceivableCreditLossExpenseReversal	6907000	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	5343000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3960000	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	49411000	usd
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	14790000	usd
CY2022Q1	us-gaap	Financing Receivable Allowance For Credit Loss Writeoff After Recovery FinancingReceivableAllowanceForCreditLossWriteoffAfterRecovery	0	usd
CY2022Q1	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-1109000	usd
CY2022Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	13681000	usd
CY2021Q4	us-gaap	Accounts And Financing Receivable Allowance For Credit Loss AccountsAndFinancingReceivableAllowanceForCreditLoss	65584000	usd
CY2022Q1	hcsg	Accounts And Financing Receivable Allowance For Credit Loss Writeoff AccountsAndFinancingReceivableAllowanceForCreditLossWriteoff	5343000	usd
CY2022Q1	hcsg	Accounts And Financing Receivable Credit Loss Expense Reversal AccountsAndFinancingReceivableCreditLossExpenseReversal	2851000	usd
CY2022Q1	us-gaap	Accounts And Financing Receivable Allowance For Credit Loss AccountsAndFinancingReceivableAllowanceForCreditLoss	63092000	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	200000	usd
CY2023Q1	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	1206000	usd
CY2022Q1	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	-5277000	usd
CY2023Q1	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-1000	usd
CY2022Q1	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-8000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1207000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-5269000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	100000	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	100000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	300000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	1400000	usd
CY2023Q1	hcsg	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	23559000	usd
CY2022Q4	hcsg	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	34445000	usd
CY2023Q1	hcsg	Property Plant And Equipment And Operating Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	44785000	usd
CY2022Q4	hcsg	Property Plant And Equipment And Operating Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	55171000	usd
CY2023Q1	hcsg	Property Plant And Equipment And Operating Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	21385000	usd
CY2022Q4	hcsg	Property Plant And Equipment And Operating Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	32196000	usd
CY2023Q1	hcsg	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	23400000	usd
CY2022Q4	hcsg	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	22975000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	2500000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	2900000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1200000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1600000	usd
CY2023Q1	hcsg	Lessee Operating Lease Termination Option Term LesseeOperatingLeaseTerminationOptionTerm	P1Y
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1387000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1386000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	232000	usd
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	355000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	450000	usd
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	82000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	2069000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	1823000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1514000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1711000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y4M24D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.051
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.042
CY2023Q1	hcsg	Right Of Use Asset And Operating Lease Liability Decrease Due To Cancellation RightOfUseAssetAndOperatingLeaseLiabilityDecreaseDueToCancellation	700000	usd
CY2022Q1	hcsg	Right Of Use Asset And Operating Lease Liability Decrease Due To Cancellation RightOfUseAssetAndOperatingLeaseLiabilityDecreaseDueToCancellation	900000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1200000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4169000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4308000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2675000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1539000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1365000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1389000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	116000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15561000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1507000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	14054000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2616000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2685000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2685000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2666000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1197000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	613000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2281000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1200000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1200000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5300000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	300000	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1700000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain EquitySecuritiesFvNiUnrealizedGain	1500000	usd
CY2022Q1	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss	4100000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	98859000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	511000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3385000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	95985000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	99601000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	229000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4630000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	95200000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	6729000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	2798000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	33048000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	35068000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	40008000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	38575000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	16200000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	18759000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	95985000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	95200000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2058000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2396000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2058000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2396000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	23300000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2375000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.56
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	207000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	13.72
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.046
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	132000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	24.14
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2450000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.45
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.53
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.06
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.040
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.015
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y10M24D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y8M12D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.395
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.366
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	31000	usd
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P5Y3M18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1713000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	34.72
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M24D
CY2023Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	900000	usd
CY2022Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	800000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	417230000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	426811000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	17556000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	15781000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	12684000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	11329000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74497000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74326000	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	21000	shares
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	7000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74518000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74333000	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.17
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.15
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.17
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.15
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3191000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3369000	shares
CY2023Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	300000000	usd
CY2023Q1	us-gaap	Line Of Credit LineOfCredit	35000000	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	25000000	usd
CY2023Q1	hcsg	Debt Instrument Covenant Number DebtInstrumentCovenantNumber	2	covenant
CY2023Q1	hcsg	Lineof Credit Facility Increase Decrease Remaining Borrowing Capacity LineofCreditFacilityIncreaseDecreaseRemainingBorrowingCapacity	-85700000	usd
CY2023Q1	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	179300000	usd

Files In Submission

Name	View Source	Status
0000731012-23-000065-index-headers.html	Edgar Link	pending
0000731012-23-000065-index.html	Edgar Link	pending
0000731012-23-000065.txt	Edgar Link	pending
0000731012-23-000065-xbrl.zip	Edgar Link	pending
ex311section302certificati.htm	Edgar Link	pending
ex312section302certificati.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hcsg-20230331.htm	Edgar Link	pending
hcsg-20230331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hcsg-20230331_cal.xml	Edgar Link	unprocessable
hcsg-20230331_def.xml	Edgar Link	unprocessable
hcsg-20230331_lab.xml	Edgar Link	unprocessable
hcsg-20230331_pre.xml	Edgar Link	unprocessable
hcsg-20230331_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
section906certificationq12.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HCSG
HEALTHCARE SERVICES GROUP INC Stock $hcsg

2023 Q2 Form 10-Q Financial Statement

#000073101223000065 Filed on April 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCSG HEALTHCARE SERVICES GROUP INC Stock $hcsg

2023 Q2 Form 10-Q Financial Statement

#000073101223000065 Filed on April 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCSG
HEALTHCARE SERVICES GROUP INC Stock $hcsg